section name header

Evidence summaries

Monotherapy Treatment of Epilepsy in Pregnancy: Congenital Malformation Outcomes in the Child

Exposure in the womb to certain antiepileptic drugs may carry an increased risk of malformation in the foetus and may be associated with specific patterns of malformation. Based on current evidence, levetiracetam and lamotrigine exposure may carry the lowest risk of overall malformation; however, data pertaining to specific malformations are lacking. Level of evidence: "C"

Summary

A Cochrane review [Abstract] 1 included 50 studies with 31 contributing to meta-analysis. All but one were non-randomised studies.

  • Carbamazepine (CBZ):Children exposed to CBZ were at a higher risk of malformation than children born to women without epilepsy (N = 1367 vs 2146, RR 2.01, 95% CI 1.20 to 3.36) and women with untreated epilepsy (N = 3058 vs 1287, RR 1.50, 95% CI 1.03 to 2.19).
  • Phenobarbital (PB): Children exposed to PB were at a higher risk of malformation than children born to women without epilepsy (N = 345 vs 1591, RR 2.84, 95% CI 1.57 to 5.13). There were significantly higher rates of specific malformations associating PB exposure with cardiac malformations.
  • Phenytoin (PHT): Children exposed to PHT were at an increased risk of malformation compared with children born to women without epilepsy (N = 477 vs 987, RR 2.38, 95% CI 1.12 to 5.03) and to women with untreated epilepsy (N = 640 vs 1256, RR 2.40, 95% CI 1.42 to 4.08).
  • Topiramate (TPM): Children exposed to TPM were at an increased risk of malformation compared with children born to women without epilepsy (N = 359 vs 442, RR 3.69, 95% CI 1.36 to 10.07).
  • Valproate (VPA): Children exposed to VPA were at a higher risk of malformation compared with children born to women without epilepsy (N = 467 vs 1936, RR 5.69, 95% CI 3.33 to 9.73) and to women with untreated epilepsy (N = 1923 vs 1259, RR 3.13, 95% CI 2.16 to 4.54). Dose of exposure mediated the risk of malformation following VPA exposure. There were significantly higher rates of specific malformations associating VPA exposure with neural tube, cardiac, oro-facial/craniofacial, and skeletal and limb malformations in comparison to other AEDs.
  • Other antiepileptic drugs (AED): There was no increased risk for major malformation for lamotrigine (LTG). Gabapentin (GPN), levetiracetam (LEV), oxcarbazepine (OXC), primidone or zonisamide (ZNS) were not associated with an increased risk, however, there were substantially fewer data for these medications.
  • AED comparisons: Children exposed to VPA had the greatest risk of malformation (10.93%, 95% CI 8.91 to 13.13). Children exposed to VPA were at an increased risk of malformation compared with children exposed to CBZ (N = 2529 vs 4549, RR 2.44, 95% CI 2.00 to 2.94), GBP (N = 1814 vs 190, RR 6.21, 95% CI 1.91 to 20.23), LEV (N = 1814 vs 817, RR 5.82, 95% CI 3.13 to 10.81), LTG (N = 2021 vs 4164, RR 3.56, 95% CI 2.77 to 4.58), TPM (N = 1814 vs 473, RR 2.35, 95% CI 1.40 to 3.95), OXC (N = 676 vs 238, RR 3.71, 95% CI 1.65 to 8.33), PB (N = 1137 vs 626, RR 1.59, 95% CI 1.11 to 2.29, PHT (N = 2319 vs 1137, RR 2.00, 95% CI 1.48 to 2.71) or ZNS (N = 323 vs 90, RR 17.13, 95% CI 1.06 to 277.48). Children exposed to CBZ were at a higher risk of malformation than those exposed to LEV (N = 3051 vs 817, RR 1.84, 95% CI 1.03 to 3.29) and children exposed to LTG (N = 3385 vs 4164, RR 1.34, 95% CI 1.01 to 1.76). Children exposed to PB were at a higher risk of malformation compared with children exposed to GBP (N = 204 vs 159, RR 8.33, 95% CI 1.04 to 50.00), LEV (N = 204 vs 513, RR 2.33, 95% CI 1.04 to 5.00) or LTG (N = 282 vs 1959, RR 3.13, 95% CI 1.64 to 5.88). Children exposed to PHT had a higher risk of malformation than children exposed to LTG (N = 624 vs 4082, RR 1.89, 95% CI 1.19 to 2.94) or to LEV (N = 566 vs 817, RR 2.04, 95% CI 1.09 to 3.85); however, the comparison to LEV was not significant in the random-effects model. Children exposed to TPM were at a higher risk of malformation than children exposed to LEV (N = 473 vs 817, RR 2.00, 95% CI 1.03 to 3.85) or LTG (N = 473 vs 3975, RR 1.79, 95% CI 1.06 to 2.94).

Clinical comments

Note

Date of latest search:

    References

    • Weston J, Bromley R, Jackson CF et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016;11():CD010224. [PubMed]

Primary/Secondary Keywords